• 1. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Recent Advances in the Study of (1S)-2-amino-1-(3-bromopyridin-4-yl)ethan-1-ol (CAS: 2227912-04-9)

The compound (1S)-2-amino-1-(3-bromopyridin-4-yl)ethan-1-ol (CAS: 2227912-04-9) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This chiral amino alcohol derivative, characterized by its 3-bromopyridin-4-yl moiety, serves as a versatile intermediate in the synthesis of biologically active molecules. Recent studies have explored its utility in the design of kinase inhibitors, antimicrobial agents, and other therapeutic compounds, highlighting its importance in modern pharmaceutical research.

One of the key areas of investigation involves the role of (1S)-2-amino-1-(3-bromopyridin-4-yl)ethan-1-ol in the development of kinase inhibitors. Kinases are critical targets in oncology and inflammatory diseases, and the bromopyridine scaffold has been shown to enhance binding affinity and selectivity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory activity against specific tyrosine kinases, with promising results in preclinical models of cancer. The study also highlighted the compound's favorable pharmacokinetic properties, such as metabolic stability and oral bioavailability.

In addition to its applications in kinase inhibition, (1S)-2-amino-1-(3-bromopyridin-4-yl)ethan-1-ol has been investigated for its antimicrobial potential. Researchers have synthesized a series of analogs incorporating this scaffold and evaluated their efficacy against drug-resistant bacterial strains. A recent report in Bioorganic & Medicinal Chemistry Letters revealed that certain derivatives exhibit broad-spectrum activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The presence of the bromine atom was found to be crucial for enhancing membrane penetration and disrupting bacterial cell wall synthesis.

The synthetic accessibility of (1S)-2-amino-1-(3-bromopyridin-4-yl)ethan-1-ol has also been a focus of recent research. Advances in asymmetric synthesis and catalytic methods have enabled the efficient production of this compound in high enantiomeric purity. A 2024 study in Organic Process Research & Development described a scalable route using chiral auxiliaries and transition metal catalysis, achieving yields exceeding 80% with minimal byproducts. This progress is expected to facilitate the large-scale production of the compound for further pharmacological evaluation.

Despite these promising developments, challenges remain in optimizing the therapeutic potential of (1S)-2-amino-1-(3-bromopyridin-4-yl)ethan-1-ol. Issues such as off-target effects and toxicity profiles need to be addressed through structural modifications and detailed preclinical studies. Future research directions may include the exploration of prodrug strategies and combination therapies to enhance efficacy and reduce adverse effects. Overall, the continued investigation of this compound holds significant promise for advancing drug discovery in multiple therapeutic areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)